<DOC>
	<DOCNO>NCT02124707</DOCNO>
	<brief_summary>This non-randomized , open-label phase II trial 38 patient recurrent metastatic SCCHN . Patients must ECOG performance status 0-1 good organ function treat six weekly cycle carboplatin , paclitaxel cetuximab . Following assessment response , treat physician discretion may continue treat weekly cetuximab maintenance disease progression . The study design evaluate whether regimen improve median overall survival ( OS ) compare historical control population treat platinum plus 5-fluorouracil ( 5-FU ) . There currently agree upon first line therapy recurrent metastatic SCCHN ; regimen option highly toxic , inconvenient resource intensive . Our study regimen use extensively induction therapy off-protocol palliative care , treatment outcome yet define clinical trial .</brief_summary>
	<brief_title>Weekly Carboplatin , Paclitaxel Cetuximab Treatment Patients With Recurrent Metastatic SCCHN</brief_title>
	<detailed_description>Because high response rate low toxicity , taxane , carboplatin , cetuximab regimen frequently adapt use palliative setting . At UNC , observe high rate response , lead symptomatic benefit low toxicity . Further , regimen de-medicalizes patient 's life several important way . First , unlike EXTREME regimen , PORT 4 day infusion require . Second , regimen give six week cytotoxic therapy . Finally , experience low rate severe toxicity , couple high rate response , may improve quality life . We aware present published result use combination palliative therapy ; adoption regimen clinical practice , documentation benefit via conduct clinical trial need . We propose study design detect improvement median OS versus historical control . The control arm EXTREME trial achieve median OS 7.4 month . We hypothesize less toxic effective 3-drug regimen result improved median OS compare control arm EXTREME ( median 7.4 month ) . The toxicity associate EXTREME primarily attributable cisplatin 5FU cytotoxic backbone toxicity consistent multiple study palliative therapy induction therapy . If 4-month improvement OS achieve acceptable toxicity , consider regimen worth study . Secondary objective include characterize change quality life ( QoL ) , symptoms toxicity . Patients encourage co-enroll UNCseq protocol exploration association genetic change clinical outcome .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Age â‰¥ 18 year old Histologically cytologically confirm recurrent metastatic Squamous Cell Carcinoma Head Neck ( SCCHN ) . All primary site eligible exclude WHO type III EBV nasopharyngeal ( WHO type I WHO type II allow long EBV negative ) ECOG performance status 01 Adequate organ marrow function define . Laboratory test complete within 14 day prior registration : ANC great equal 1,500/mm3 , Platelets great equal 100,000/mm3 , HgB great 9g/dL ( acceptable reach transfusion ) , Total bilirubin less equal 1.5mg/dL , Albumin great 2.5 g/dL , AST ( SGOT ) /ALT ( SGPT ) less equal 2.5X institutional upper limit normal , alkaline phosphatase less equal 2.5 x upper limit normal , GFR great 30 mL/min ( standard Cockroft Gault formula measure via 24 hour urine collection ) Women childbearing potential ( WOCBP ) negative serum urine pregnancy test within 7 day D1 treatment WOCBP men must agree use adequate contraception prior study entry duration treatment protocol ; adequate contraception define medically recommend method ( combination method ) per standard care . Cancer must consider incurable treat clinician Ability understand willingness sign write informed consent document History prior cumulative exposure &gt; 300mg/m2 cisplatin , AUC 18 carboplatin , combine equivalent within one year prior enrollment Surgery radiation within four week prior D1 treatment protocol Prior systemic chemotherapy unless part definitiveintent ( curative intent ) treatment 6 month study entry Other active , invasive malignancy require ongoing therapy expect require systemic therapy within two year ; localize squamous cell carcinoma skin , basalcell carcinoma skin , carcinoma insitu cervix , malignancy require locally ablative therapy result exclusion Pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Head neck cancer</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Phase II</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cetuximab</keyword>
</DOC>